DaCapo Brainscience

DaCapo Brainscience is a precision medicine company dedicated to developing transformative therapies for neurodegenerative and neuropsychiatric diseases. The company utilizes a proprietary platform that integrates human-derived data, including iPSC models and multi-omics, with advanced computational biology to identify specific disease drivers within patient subpopulations. By targeting these distinct biological mechanisms, DaCapo aims to move beyond the traditional broad-spectrum approach to CNS disorders, starting with Parkinson's disease. Founded by industry veterans and leading academic scientists from the Whitehead Institute and MIT, the company is focused on delivering the right drug to the right patient at the right time. DaCapo is currently in the pre-clinical stage and is backed by prominent life science investors.